| 臺大學術典藏 |
2021-03-10T02:36:32Z |
Response to Sung, Rosenberg, and Yang
|
Lin C.-H.; Yap Y.S.; Lee K.-H.; Yeo W.; Ueno T.; Li H.; Huang S.-M.; YEN-SHEN LU |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Author Correction: Immunofluorescence can assess the efficacy of mTOR pathway therapeutic agent Everolimus in breast cancer models (Scientific Reports, (2019), 9, 1, (10898), 10.1038/s41598-019-45319-4)
|
Kuo C.-T.; Chen C.-L.; Li C.-C.; Huang G.-S.; Ma W.-Y.; Hsu W.-F.; Lin C.-H.; YEN-SHEN LU; Wo A.M. |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
Neratinib plus capecitabine versus lapatinib plus capecitabine in HER2-positive metastatic breast cancer previously treated with ? 2 HER2-directed regimens: Phase III NALA trial
|
Saura C.; Oliveira M.; Feng Y.-H.; Dai M.-S.; Chen S.-W.; Hurvitz S.A.; Kim S.-B.; Moy B.; Delaloge S.; Gradishar W.; Masuda N.; Palacova M.; Trudeau M.E.; Mattson J.; Yap Y.S.; Hou M.-F.; De Laurentiis M.; Yeh Y.-M.; Chang H.-T.; Yau T.; Wildiers H.; Haley B.; Fagnani D.; YEN-SHEN LU; Crown J.; Lin J.; Takahashi M.; Takano T.; Yamaguchi M.; Fujii T.; Yao B.; Bebchuk J.; Keyvanjah K.; Bryce R.; Brufsky A.; NALA Investigators |
| 臺大學術典藏 |
2021-03-10T02:36:31Z |
A case-control study of perfluoroalkyl substances and the risk of breast cancer in Taiwanese women
|
Tsai M.-S.;Chang S.-H.;Kuo W.-H.;Kuo C.-H.;Li S.-Y.;Wang M.-Y.;Chang D.-Y.;Yen-Shen Lu;Huang C.-S.;Cheng A.-L.;Lin C.-H.;Chen P.-C.; Tsai M.-S.; Chang S.-H.; Kuo W.-H.; Kuo C.-H.; Li S.-Y.; Wang M.-Y.; Chang D.-Y.; YEN-SHEN LU; Huang C.-S.; Cheng A.-L.; Lin C.-H.; Chen P.-C. |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HR? advanced breast cancer
|
Tolaney S.M.; Im Y.-H.; Calvo E.; YEN-SHEN LU; Hamilton E.; Forero-Torres A.; Bachelot T.; Maur M.; Fasolo A.; Tiedt R.; Nardi L.; Stammberger U.; Abdelhady A.M.; Ruan S.; Lee S.C. |
| 臺大學術典藏 |
2021-03-10T02:36:30Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
YEN-SHEN LU; Lee K.S.; Chao T.-Y.; Tseng L.-M.; Chitapanarux I.; Chen S.-C.; Liu C.-T.; Sohn J.; Kim J.H.; Chang Y.-C.; Yang Y.; Shotelersuk K.; Jung K.H.; Valenti R.; Slader C.; Gao M.; Park Y.H. |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
|
Schmid P.; Sablin M.-P.; Bergh J.; Im S.-A.; YEN-SHEN LU; Mart?nez N.; Neven P.; Lee K.S.; Morales S.; P?rez-Fidalgo J.A.; Adamson D.; Gon?alves A.; Prat A.; Jerusalem G.; Schlieker L.; Espadero R.-M.; Bogenrieder T.; Huang D.C.-L.; Crown J.; Cort?s J. |
| 臺大學術典藏 |
2021-03-10T02:36:29Z |
Alpelisib plus fulvestrant for PIK3CA-mutated, hormone receptor-positive, human epidermal growth factor receptor-2�Vnegative advanced breast cancer: final overall survival results from SOLAR-1
|
Andr? F.; Ciruelos E.M.; Juric D.; Loibl S.; Campone M.; Mayer I.A.; Rubovszky G.; Yamashita T.; Kaufman B.; YEN-SHEN LU; Inoue K.; P?pai Z.; Takahashi M.; Ghaznawi F.; Mills D.; Kaper M.; Miller M.; Conte P.F.; Iwata H.; Rugo H.S. |
| 臺大學術典藏 |
2021-03-03T10:26:44Z |
A phase ib study of alpelisib or buparlisib combined with tamoxifen plus goserelin in premenopausal women with HR-positive HER2-negative advanced breast cancer
|
Yen-Shen Lu; Lee, Keun Seok; Chao, Tsu Yi; Tseng, Ling Ming; Chitapanarux, Imjai; Chen, Shin Cheh; Liu, Chien Ting; Sohn, Joohyuk; Kim, Jee Hyun; Chang, Yuan Ching; Yang, Youngsen; Shotelersuk, Kanjana; Jung, Kyung Hae; Valenti, Roberta; Slader, Cassandra; Gao, Melissa; Park, Yeon Hee |
| 臺大學術典藏 |
2021-03-03T10:26:43Z |
Phase ib study of ribociclib plus fulvestrant and ribociclib plus fulvestrant plus pi3k inhibitor (alpelisib or buparlisib) for HRþ advanced breast cancer
|
Tolaney, Sara M.; Im, Young Hyuck; Calvo, Emiliano; Yen-Shen Lu; Hamilton, Erika; Forero-Torres, Andres; Bachelot, Thomas; Maur, Michela; Fasolo, Angelica; Tiedt, Ralph; Nardi, Lisa; Stammberger, Uz; Abdelhady, Ahmed M.; Ruan, Shiling; Lee, Soo Chin |
| 臺大學術典藏 |
2021-02-02T09:21:43Z |
A phase Ib/II study of xentuzumab, an IGF-neutralising antibody, combined with exemestane and everolimus in hormone receptor-positive, HER2-negative locally advanced/metastatic breast cancer
|
Schmid, Peter; Sablin, Marie Paule; Bergh, Jonas; Im, Seock Ah; Yen-Shen Lu; Martínez, Noelia; Neven, Patrick; Lee, Keun Seok; Morales, Serafín; Pérez-Fidalgo, J. Alejandro; Adamson, Douglas; Gonçalves, Anthony; Prat, Aleix; Jerusalem, Guy; Schlieker, Laura; Espadero, Rosa Maria; Bogenrieder, Thomas; Huang, Dennis Chin Lun; Crown, John; Cortés, Javier |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
Phase II trial combining paclitaxel with 24-hour infusion cisplatin for chemotherapy-na?ve patients with locally advanced or metastatic breast carcinoma
|
Cheng A.-L.;Chang K.-J;Chen M.M;Bu C.-F;Yen-Shen Lu;Chao T.-Y;Huang C.-S;Hsu C; Hsu C; Huang C.-S; Chao T.-Y; YEN-SHEN LU; Bu C.-F; Chen M.M; Chang K.-J; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
A phase II study of weekly methotrexate, cisplatin, and 24-hour infusion of high-dose 5-fluorouracil and leucovorin (MP-HDFL) in patients with metastatic and recurrent esophageal cancer-improving toxicity profile by infusional schedule and double biochemical modulation of 5-fluorouracil
|
Hsu C; Yang C.-H; YEN-SHEN LU; Lin C.-C; Bu C.-F; Yeh K.-H.; Yeh K.-H.;Bu C.-F;Lin C.-C;Yen-Shen Lu;Yang C.-H;Hsu C;Cheng A.-L;Hsu C.-H; Hsu C.-H; Cheng A.-L |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
Basal levels and patterns of anticancer drug-induced activation of nuclear factor-�eB (NF-�eB), and its attenuation by tamoxifen, dexamethasone, and curcumin in carcinoma cells
|
Cheng A.-L.;Gao M;Liao C.-M;Lai G.-M;Yen-Shen Lu;Yeh P.-Y;Chuang S.-E; Chuang S.-E; Yeh P.-Y; YEN-SHEN LU; Lai G.-M; Liao C.-M; Gao M; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:11Z |
MRI phenotype is associated with response to doxorubicin and cyclophosphamide neoadjuvant chemotherapy in stage III breast cancer
|
Tripathy D; Rugo H; Park J; Hwang S; Kuerer H; Sudilovsky D; YEN-SHEN LU; Hylton N.; Partridge S; Kaplan E; Hylton N.;Yen-Shen Lu;Sudilovsky D;Kuerer H;Hwang S;Park J;Rugo H;Tripathy D;Partridge S;Kaplan E;Esserman L; Esserman L |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Recent advances in the management of primary breast cancers
|
Huang C.-S.;Kuo S.-H;Yen-Shen Lu; YEN-SHEN LU; Kuo S.-H; Huang C.-S. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Phase II study of combination doxorubicin, interferon-�\, and high-dose tamoxifen treatment for advanced hepatocellular carcinoma
|
Cheng A.-L.;Wu C.-Y;Hsu C.-H;Yang C.-H;Yeh K.-H;Kuo S.-H;Li C.-C;Hsu C;Yen-Shen Lu; YEN-SHEN LU; Hsu C; Li C.-C; Kuo S.-H; Yeh K.-H; Yang C.-H; Hsu C.-H; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
High-dose Tamoxifen Modulates Drug Resistance to Doxorubicin, Dacarbazine and Ifosfamide in Metastatic Uterine Leiomyosarcoma
|
Cheng A.-L.;Hsiao C.-H;Yen-Shen Lu;Yeh K.-H; Yeh K.-H; YEN-SHEN LU; Hsiao C.-H; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:10Z |
Weekly gemcitabine plus 24-h infusion of high-dose 5-fluorouracil/ leucovorin for locally advanced or metastatic carcinoma of the biliary tract
|
Cheng A.-L.;Wu C.-Y;Chen J.-S;Li C.-C;Liu H.-T;Hsu C.-H;Yen-Shen Lu;Yeh K.-H;Yang C.-H;Shen Y.-C;Hsu C; Hsu C; Shen Y.-C; Yang C.-H; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Liu H.-T; Li C.-C; Chen J.-S; Wu C.-Y; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly paclitaxel and 24-hour infusion of high-dose 5-fluorouracil and leucovorin in the treatment of recurrent or metastatic gastric cancer
|
Yeh K.-H;Yen-Shen Lu;Hsu C.-H;Lin J.-F;Hsu C;Kuo S.-H;Li Jr. S;Cheng A.-L.; Yeh K.-H; YEN-SHEN LU; Hsu C.-H; Lin J.-F; Hsu C; Kuo S.-H; Li Jr. S; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Phase II study of weekly vinorelbine and 24-h infusion of high-dose 5-fluorouracil plus leucovorin as first-line treatment of advanced breast cancer
|
Yeh K.H;Yen-Shen Lu;Hsu C.H;Lin J.F;Chao H.J;Huang T.C;Chung C.Y;Chang C.S;Yang C.H;Cheng A.L.; Yeh K.H; YEN-SHEN LU; Hsu C.H; Lin J.F; Chao H.J; Huang T.C; Chung C.Y; Chang C.S; Yang C.H; Cheng A.L. |
| 臺大學術典藏 |
2020-05-25T06:52:09Z |
Angiogenic response of locally advanced breast cancer to neoadjuvant chemotherapy evaluated with parametric histogram from dynamic contrast-enhanced MRI
|
Tseng W.-Y.I.;Yen-Shen Lu;Chen J.-H;Liu Y.-J;Huang C.-S;Chang Y.-C; Chang Y.-C; Huang C.-S; Liu Y.-J; Chen J.-H; YEN-SHEN LU; Tseng W.-Y.I. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Glucocorticoids enhance cytotoxicity of cisplatin via suppression of NF-�eB activation in the glucocorticoid receptor-rich human cervical carcinoma cell line SiHa
|
Yen-Shen Lu;Yeh P.-Y;Chuang S.-E;Gao M;Kuo M.-L;Cheng A.-L.; YEN-SHEN LU; Yeh P.-Y; Chuang S.-E; Gao M; Kuo M.-L; Cheng A.-L. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Phase I study of biweekly gemcitabine followed by oxaliplatin and simplified 48-h infusion of fluorouracil/leucovorin for advanced pancreatic cancer
|
Ch'Ang H.-J;Wang C.-C;Cheng A.-L;Hsu C;Yen-Shen Lu;Chang M.-C;Lin J.-T;Wang H.-P;Shiah H.-S;Liu T.-W;Chang J.-Y;Whang-Peng J;Chen L.-T.; Ch'ang H.-J; Wang C.-C; Cheng A.-L; Hsu C; YEN-SHEN LU; Chang M.-C; Lin J.-T; Wang H.-P; Shiah H.-S; Liu T.-W; Chang J.-Y; Whang-Peng J; Chen L.-T. |
| 臺大學術典藏 |
2020-05-25T06:52:08Z |
Effects of glucocorticoids on the growth and chemosensitivity of carcinoma cells are heterogeneous and require high concentration of functional glucocorticoid receptors
|
Kuo M.-L; Kuo S.-H; Cheng A.-L.; Yeh K.-H; Yeh P.-Y; Lien H.-C; YEN-SHEN LU; Yen-Shen Lu;Lien H.-C;Yeh P.-Y;Yeh K.-H;Kuo M.-L;Kuo S.-H;Cheng A.-L. |
